Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
CASI
$2.62
Casi Pharmaceuticals
($.13)
(4.73%)
CASI
Earnings Whisper ®
N/A
3rd Quarter September 2023
Consensus: ($0.56)
Revenue: $10.40 Mil
Friday
Nov 10
7:00 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Friday, August 11, 2023
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
What do you expect when CASI reports earnings?
Beat
Meet
Miss
Where is CASI's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.
Expectations
›
Casi Pharmaceuticals